Navigation Links
Statins May Not Be as Helpful for Those Without Heart Disease
Date:6/29/2010

By Steven Reinberg
HealthDay Reporter

MONDAY, June 28 (HealthDay News) -- Despite being used widely to lower cholesterol levels, statins don't appear to reduce the chances of death in people at risk of developing cardiovascular disease, British scientists have found.

Statins are used widely to treat and prevent cardiovascular disease. They are given both to people with heart disease and -- in more recent years -- to those who are at risk for heart disease but who have no history of it.

In people with a history of heart disease, statin therapy is known to reduce the risk of complications from the illness and premature death, the British researchers noted. But they said their new meta-analysis of previously published studies -- along with the known risks that statins pose to certain people -- calls into question the benefits of statins to prevent the development of heart disease.

One U.S. expert said the findings need to be taken in context.

"Statin therapy has been demonstrated in individual randomized clinical trials and in pooled analysis to prevent fatal and nonfatal cardiovascular events in individuals without established cardiovascular disease," said Dr. Gregg C. Fonarow, director of the Ahmanson-UCLA Cardiomyopathy Center at the University of California, Los Angeles.

"In eligible men and women without contraindications, statin therapy -- along with lifestyle modifications-- represents one of the most effective means to prevent myocardial infarction [heart attack] and stroke," he said.

This new analysis examined a number of primary prevention trials to determine, during the first few years after statin therapy is initiated, whether there is a reduction in deaths from all causes, Fonarow noted.

"As expected, with primary prevention studies having only a mean duration of follow-up of 3.7 years, a reduction in all-cause mortality was not observed," he said. "To detect a reduction in all-cause mortality in a primary prevention population, studies of longer duration or confined to only the most potent statins would be required."

This study also shows the safety of statin therapy, even in apparently healthy people, as "there was no evidence for an increase in non-cardiovascular mortality," Fonarow said.

The report is published in the June 28 issue of the Archives of Internal Medicine.

For the study, Dr. Sreenivasa Rao Kondapally Seshasai, from the cardiovascular epidemiology unit at the University of Cambridge and Addenbrooke's Hospital, Cambridge, and colleagues pooled data from 11 studies, which included 65,229 participants. In all, 32,623 of these individuals took statins and 32,606 were taking a placebo.

During almost four years of follow-up, 2,793 people died. Among those who died, 1,447 were taking a placebo and 1,346 were taking statins, the researchers found. This difference was not statistically significant, they noted.

Even though the statins were doing their job and the levels of LDL, or "bad," cholesterol were higher among people taking the placebo than those taking statins, there was no association between risk of dying and LDL levels, Seshasai's group found.

Currently, some 33.5 million older Americans, according to the American Heart Association, are taking a statin or have risk factors that suggest a need for statin therapy. However, another 11 million older Americans at risk for heart disease may be eligible for statin therapy, according to the association.

Previous data suggests that people who have cardiovascular disease benefit from statin therapy. Various studies have found that these drugs prevent complications from cardiovascular disease and lower the risk of dying in this population.

However, there is much less evidence that statins lower the risk of dying prematurely in people without heart disease.

"Current prevention guidelines endorse statin therapy for subjects at high global risk of incident cardiovascular disease as a means to reduce fatal and nonfatal vascular events," the researchers write. "Due consideration is needed in applying statin therapy in lower-risk primary prevention populations," they conclude.

More information

For more information on statins, visit the U.S. National Library of Medicine.

SOURCES: Gregg C. Fonarow, M.D., professor, medicine, and director, Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles; June 28, 2010, Archives of Internal Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Statins Show Promise Against Sickle Cell
2. More Evidence That Statins Cut Stroke Risk
3. Statins May Benefit Prostate Cancer Patients
4. Alternative to Statins Shows Promise
5. Statins may slow progression of multiple sclerosis, new study finds
6. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
7. Do Statins Lower Male Sex Drive?
8. Statins Wont Lower Colon Cancer Risk
9. Statins decrease risk of clot-related diseases
10. Some statins have unintended effects and warrant closer monitoring, study finds
11. Too Many Stroke Patients Go Without Statins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Statins May Not Be as Helpful for Those Without Heart Disease 
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: